// App-Quantinova.ai

M4191 2016 AHA : Impact of Spironolactone on Profibrotic Markers in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial (TOPCAT)

Researchers

Presenter

  • Simon de Denus

Principal Investigators

  • Brian L Claggett

  • Akshay S Desai

  • Michael R Zile

  • Inder S Anand

  • Sanjiv J Shah

  • Martin G Sirois

  • Scott D Solomon

  • Pitt Bertram

  • Marc A Pfeffer

  • Jean L Rouleau

Medical Centers

  • Brigham & Women's Hospital, Boston, MA

  • Ralph H Johnson Dept of Veterans Affairs Medical Ctr and Medical Univ of South Carolina, Charleston, SC

  • Brigham & Women's Hospital, Boston, MA

  • Northwestern Memorial Hospital, Chicago, IL

  • University of Minnesota and Minneapolis VA Medical Center, Minneapolis, MN

  • Univ of Michigan Sch of Med, Ann Arbor, MI

  • Montreal Heart Institute, Montreal, Quebec, Canada

Locations

  • United States

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Heart failure with preserved ejection fraction

  • Myocardial fibrosis

  • Cardiac fibrosis

  • Congestive heart failure

Biomarkers

  • Chloride Channel Accessory 1

  • Procollagen III N-Terminal Propeptide

  • Galectin-3

  • Matrix metallopeptidase 9

  • Matrix metalloproteinase

  • Matrix metalloproteinase 2

  • TIMP Metallopeptidase Inhibitor 1

Drug/Treatment

  • Spironolactone

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved